Point Therapeutics' Diabetes Program Presented at American Diabetes Association 66th Annual Scientific Sessions; Chronic Admini
June 12 2006 - 7:10AM
Business Wire
Point Therapeutics, Inc. (NASDAQ: POTP) presented a preclinical
poster on the Company's lead diabetes compound, PT-630, at the
American Diabetes Association 66th Annual Scientific Sessions on
Sunday, June 11, 2006. PT-630 is an inhibitor of DPP-4, which is a
widely recognized target for the treatment of diabetes. During this
presentation, the Company presented the structure of PT-630 for the
first time. In addition, the Company presented head to head
preclinical data that differentiated PT-630 from both a
cyanopyrrolidine (CP) DPP-4 inhibitor and from metformin in studies
in Zucker Diabetic Fatty (ZDF) rats. In single dose acute studies
of PT-630 and the CP-inhibitor, PT-630 increased insulin secretion,
reduced glucose excursion and increased GLP-1 levels at similar
levels to the CP-inhibitor in animals. However, even with a single
dose administration, PT-630 demonstrated longer term benefits in
both elevation of GLP-1 levels {24 and 48 oral glucose tolerance
test (OGTT)} and lowering of plasma glucose (4 hours post OGTT) at
later times than the CP-inhibitor. In a chronic dosing study of
PT-630, the CP-inhibitor and metformin, PT-630 is differentiated
from both the CP-inhibitor and metformin in animals. After 44 days
of daily dosing, PT-630 was more effective than the other two study
compounds in improving parameters associated with the progression
of type 2 diabetes. Specifically, there were improvements in whole
body sensitivity to insulin, a 50% reduction in fasting plasma
triglycerides and glucose levels and a 1.7% reduction (a 26.4%
reduction compared to the controlled treated group) in HbA1c. There
were no such reductions in triglycerides and glucose levels with
metformin and the CP-inhibitor, and HbA1c was only reduced by 0.9%
and 0.5%, respectively, with metformin and the CP-inhibitor. All of
the above suggests the ability of PT-630 to achieve glucose control
in type 2 diabetes over the long-term. "The fact that in
preclinical studies, PT-630, even with a single-dose
administration, demonstrates longer term benefits in both elevation
of GLP-1 levels and lowering of plasma glucose at later times than
the CP-inhibitor suggest that PT-630 is a longer lasting inhibitor
of DPP-4 than the CP-inhibitor," said Nazneen Aziz, Vice President
of External Research at Point Therapeutics. "The cumulative benefit
of PT-630 in chronic dosing preclinical studies is also promising
because it suggests that PT-630 may have more comprehensive
anti-diabetes activity than both of the other compounds evaluated
when metabolic parameters associated with long-term progression of
the disease are measured." About PT-630: PT-630, Point
Therapeutics' lead diabetes compound, is an inhibitor of DPP-4,
which is a widely recognized target in the treatment of diabetes.
DPP-4 degrades the active form of GLP-1, an intestinal peptide
hormone responsible for regulating blood glucose levels. When DPP-4
is inhibited, it leads to an elevation in the circulating pool of
active GLP-1, thereby greatly improving the control of blood
glucose levels in type 2 diabetes. Active GLP-1 is also thought to
have beneficial effects on pancreatic beta cell mass. About Point
Therapeutics, Inc.: Point is a Boston-based biopharmaceutical
company developing a portfolio of dipeptidyl peptidase (DPP)
inhibitors for use in cancer, type 2 diabetes and as vaccine
adjuvants. Point is currently studying its lead product candidate,
talabostat, in two Phase 3 trials in non-small cell lung cancer.
Point is also studying talabostat in several Phase 2 trials,
including as a single-agent in metastatic melanoma, in combination
with cisplatin in metastatic melanoma, in combination with
rituximab in advanced chronic lymphocytic leukemia, and in
combination with gemcitabine in metastatic pancreatic cancer. In
addition, Point's portfolio includes two other DPP inhibitors in
preclinical development--PT-630 for type 2 diabetes and PT-510 as a
vaccine adjuvant. Certain statements contained herein are not
strictly historical and are "forward looking" statements as defined
in the Private Securities Litigation Reform Act of 1995. This
information includes statements with respect to the company's
clinical development programs and the timing of initiation and
completion of its clinical trials. Forward-looking statements are
statements that are not historical facts, and can be identified by,
among other things, the use of forward-looking language, such as
"believes," "feels," "expects," "may," "will," "should," "seeks,"
"plans," "schedules to," "projects," "anticipates" or "intends" or
the negative of those terms, or other variations of those terms of
comparable language, or by discussions of strategy or intentions. A
number of important factors could cause actual results to differ
materially from those projected or suggested in the forward looking
statement, including the risk factors described in Point's
quarterly report on Form 10-Q for the quarter ended March 31, 2006
and from time to time in Point's periodic and other reports filed
with the Securities and Exchange Commission.
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jul 2023 to Jul 2024